Clindamycin And Benzoyl Peroxide
Clindamycin And Benzoyl Peroxide Prescribing Information
During clinical trials, the most frequently reported adverse event in the clindamycin and benzoyl peroxide gel treatment group was dry skin (12%). The Table below lists local adverse events reported by at least 1% of patients in the clindamycin and benzoyl peroxide gel and vehicle groups.
Local Adverse Events – all causalities in >/= 1% of patients | ||
Clindamycin and Benzoyl Peroxide n=420 | Vehicle n=168 | |
Application site reaction | 13 (3%) | 1 (<1%) |
Dry skin | 50 (12%) | 10 (6%) |
Pruritus | 8 (2%) | 1 (<1%) |
Peeling | 9 (2%) | - |
Erythema | 6 (1%) | 1 (<1%) |
Sunburn | 5 (1%) | - |
The actual incidence of dry skin might have been greater were it not for the use of a moisturizer in these studies.
Anaphylaxis, as well as allergic reactions leading to hospitalization, have been reported during post-marketing use of clindamycin/benzoyl peroxide products. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Chemically, clindamycin phosphate is (C18H34ClN2O8PS). The structural formula for clindamycin is represented below:
Clindamycin phosphate has a molecular weight of 504.96 g/mol and its chemical name is Methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl-
Chemically, benzoyl peroxide is (C14H10O4). It has the following structural formula:
Benzoyl peroxide has a molecular weight of 242.23 g/mol.
Each gram of
An
Benzoyl peroxide has been shown to be absorbed by the skin where it is converted to benzoic acid. Less than 2% of the dose enters systemic circulation as benzoic acid. It is suggested that the lipophilic nature of benzoyl peroxide acts to concentrate the compound into the lipid-rich sebaceous follicle.